The global pharmaceutical industry experienced a 16% drop in company filings mentions of cybersecurity in Q3 2023 compared with the previous quarter, with the highest share accounted for by BeiGene with 26% year-on-year decrease, according to GlobalDataâ€™s analysis of over 450 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q3 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, cybersecurity was one of the most frequently referenced themes in Q3 2023, ranking highest in terms of mentions, ahead of electronic medical record (emr) systems and cyber insurance, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, BeiGene had the greatest increase in references for cybersecurity in Q3 2023, compared with the previous quarter. GlobalData identified 42 cybersecurity-related sentences in the company's filings - 3% of all sentences - and a decrease of 26% in Q3 2023 compared with Q3 2022. Merckâ€™s mentions of cybersecurity rose by 88% to 32 and Seagenâ€™s by 41% to 31 and Alnylam Pharmaceuticalsâ€™s by 5% to 21.
GlobalDataâ€™s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for cybersecurity in Q3 2023 was 123.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q3 2023, buy the report here.